Early MS Detection Test Developed: First Test Results
Breakthrough Study reveals Early Immunological Predictor for Multiple Sclerosis
Table of Contents
Vienna, Austria – A groundbreaking study published in Nature Communications has identified a highly accurate method for predicting the onset of Multiple Sclerosis (MS) years before clinical symptoms manifest. The research, conducted by scientists at the Medical University of Vienna (MedUni Vienna), focuses on detecting specific autoantibodies linked to the Epstein-Barr virus (EBV), offering a potential paradigm shift in early diagnosis and intervention for this debilitating neurological disease.
EBV Infection and MS: A stronger Link Revealed
Multiple Sclerosis (MS) is a chronic inflammatory disease affecting the central nervous system, impacting an estimated 2.8 million people globally. While the exact causes are complex, a strong association with the Epstein-Barr virus (EBV) has long been suspected. EBV infects the vast majority of the population (90-95%) during their lifetime, often asymptomatically or as infectious mononucleosis (glandular fever). In a subset of individuals, this viral infection appears to trigger a misguided immune response, leading the immune system to attack the body’s own neural tissues.
This new research provides compelling evidence for this link, demonstrating that infection can be detected in almost all MS cases.
Autoantibodies as Early Warning Signs
The core of the breakthrough lies in the detection of autoantibodies – antibodies that mistakenly target the body’s own structures. Specifically, the study zeroes in on antibodies directed against a particular segment of the EBV protein EBNA-1 (Epstein-Barr nuclear Antigen 1). These antibodies have been found to appear within three years of an EBV infection, significantly preceding the emergence of any observable MS symptoms.
“Our investigations show that people in whom these antibodies are detectable at least two measurement times develop an MS with a high probability in the following years,” states study author Hannes Vietzen. The retrospective study analyzed blood samples from over 700 MS patients and more than 5,000 control individuals. In a portion of the cohort, the precise timing of the initial EBV infection could be clearly established, revealing a strong correlation between consistently high antibody levels and a very high risk of rapid MS development.
MS Predictable Long Before Symptoms Appear
The findings underscore a critical insight: the early stages of MS development are immunologically recognizable long before the first clinical signs emerge. Study director Elisabeth Puchhammer-Stöckl, head of the MediUni Vienna Center, elaborates, ”Our study shows that a very early phase of MS disease development is already immunologically recognizable long before the occurrence of the first symptoms.”
This contrasts with other biomarkers, such as Neurofilament Light Chain (NFL) or Glial Fibrillary Acidic Protein (GFAP), which indicate nerve cell damage and typically rise later in the disease progression. The newly identified EBNA-1 specific autoantibody test could therefore serve as a vital tool for identifying individuals at high risk of developing MS.
Potential for Early Intervention and prevention
The implications for patient care are profound. “It would be possible to examine and treat these people so early that the outbreak of the MS can be delayed or maybe even prevented,” suggests co-attendant Paulus Rommer. This proactive approach could revolutionize how MS is managed, shifting the focus from treating established disease to preventing its onset or significantly slowing its progression.
Looking ahead, Thomas Berger, head of the university clinic for neurology at MedUni Vienna, envisions broader applications: “Because of our results, we are discussing a screening of population groups with an increased MS risk – such as after Pfeiffer’s glandular fever.” While further studies are necessary before the test can be implemented in clinical practice, this research marks a notable leap forward in understanding and perhaps controlling Multiple Sclerosis.
Publication Details
The study, titled “Early Identification of Individuals at Risk for Multiple Sclerosis by Quantification of EBNA-1381-452-specific Antibody Titers,” is published in the prestigious journal nature Communications.
DOI: 10.1038/S41467-025-61751-9
Link: https://www.nature.com/articles/s41467-025-61751-9